Literature DB >> 10971132

Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon.

M Hijikata1, Y Ohta, S Mishiro.   

Abstract

The interferon (IFN)-inducible MxA protein is known to play an important role in the host defense against certain viruses. We aimed to see if any genetic polymorphism in the promoter region of the MxA gene is associated with the IFN responsiveness of hepatitis C virus (HCV)-infected patients. Initially we sequenced the promoter region of the MxA gene in 12 subjects and found a polymorphic site. We then constructed a specific PCR-RFLP system for this site and subjected 63 samples from chronic hepatitis C patients who were nonresponders (NR) to IFN therapy to it, 52 with sustained response (SR), and 42 healthy controls. Subjects were all Japanese, and unrelated. A single nucleotide polymorphism (SNP) was identified in the MxA promoter region: G/T alleles at nt position -88. Interestingly, this SNP was involved in a genetic element highly homologous to the IFN-stimulated response element consensus sequence, and the G-to-T change there makes this homology a little greater. The rate of G.G homozygosity was 31% in the SR patients, significantly lower than in the NR patients (62%, p = 0.0009), while that of healthy controls was between the two groups (48%). Differences in HCV genotypes did not influence this result. Based on these findings, we propose that the SNP of the MxA promoter at nt -88 identified in this study affects the expression of MxA protein, and may thus be associated with the response of HCV patients to IFN. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10971132     DOI: 10.1159/000025035

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  35 in total

Review 1.  Genetics of liver disease: immunogenetics and disease pathogenesis.

Authors:  P T Donaldson
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

Review 2.  Assessing gene-gene interactions in pharmacogenomics.

Authors:  Hsien-Yuan Lane; Guochuan E Tsai; Eugene Lin
Journal:  Mol Diagn Ther       Date:  2012-02-01       Impact factor: 4.074

3.  Activation of type I interferon-dependent genes characterizes the "core response" induced by CpG DNA.

Authors:  Folkert Steinhagen; Corinna Meyer; Debra Tross; Mayda Gursel; Takahiro Maeda; Sven Klaschik; Dennis M Klinman
Journal:  J Leukoc Biol       Date:  2012-07-02       Impact factor: 4.962

4.  A support vector machine approach to assess drug efficacy of interferon-alpha and ribavirin combination therapy.

Authors:  Eugene Lin; Yuchi Hwang
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

5.  Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C.

Authors:  Xiaowen Su; Leland J Yee; KyungAh Im; Shannon L Rhodes; YongMing Tang; Xiaomei Tong; Charles Howell; Darmendra Ramcharran; Hugo R Rosen; Milton W Taylor; T Jake Liang; Huiying Yang
Journal:  J Hepatol       Date:  2008-05-20       Impact factor: 25.083

6.  The myxovirus resistance A (MxA) gene -88G>T single nucleotide polymorphism is associated with prostate cancer.

Authors:  Shanora Glymph; Sanjay Mandal; Ashley Evans Knowell; Fisseha Abebe; Jaideep Chaudhary
Journal:  Infect Genet Evol       Date:  2013-02-22       Impact factor: 3.342

7.  Current status of novel antifibrotic therapies in patients with chronic liver disease.

Authors:  Michal Cohen-Naftaly; Scott L Friedman
Journal:  Therap Adv Gastroenterol       Date:  2011-11       Impact factor: 4.409

8.  IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients.

Authors:  Mostafa K El Awady; Noha G Bader El Din; Ashraf Tabll; Yaser El Hosary; Ashraf O Abdel Aziz; Hesham El Khayat; Mohsen Salama; Tawfeek H Abdelhafez
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

9.  Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Authors:  Tania Mara Welzel; Timothy R Morgan; Herbert L Bonkovsky; Deepa Naishadham; Ruth M Pfeiffer; Elizabeth C Wright; Amy A Hutchinson; Andrew T Crenshaw; Arman Bashirova; Mary Carrington; Myhanh Dotrang; Richard K Sterling; Karen L Lindsay; Robert J Fontana; William M Lee; Adrian M Di Bisceglie; Marc G Ghany; David R Gretch; Stephen J Chanock; Raymond T Chung; Thomas R O'Brien
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

10.  2'-5'-Oligoadenylate synthetase single-nucleotide polymorphisms and haplotypes are associated with variations in immune responses to rubella vaccine.

Authors:  Iana H Haralambieva; Neelam Dhiman; Inna G Ovsyannikova; Robert A Vierkant; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Hum Immunol       Date:  2010-01-31       Impact factor: 2.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.